Project Retrovir (Pre-FRP → FRP Transition Draft)

Project Retrovir (Pre-FRP → FRP Transition Draft) Author: Mark Anthony Brewer, Brewtanius Ink LLC Date: September 2025 1. Introduction This document reframes earlier claims under the Foundational Recognition Protocol (FRP). Prior drafts presented speculative biomedical ideas as therapeutic candidates without meeting the evidentiary threshold of clinical trial registry data. This rewrite sets a new baseline: a timestamped, transparent exploratory note on KRAS-related oncology research, explicitly not a clinical claim. 2. Scope & Intent Scope: Capture and timestamp preliminary insights into viral-vector and retrotransposon-inspired approaches to disrupting KRAS oncogenic pathways. Intent: Provide a record of hypothesis-generation for future collaboration, critique, or lab investigation—not to claim a therapeutic candidate. Status: FRP-Compliant Draft — Not a therapy; not a preclinical trial. 3. Methodological Commitments To align with the Foundational Recognition Protocol, this document and its related artifacts are governed by a new set of commitments designed for transparency and verifiability. Temporal Integrity: This draft is cryptographically hashed (SHA-256) and timestamped with OpenTimestamps. This provides a public, immutable, and third-party verifiable record of when the work existed.1 Transparency: No therapeutic efficacy is implied; this is a hypothesis-only draft. All claims of "Project Retrovir" being "successful" or having discovered a drug candidate are formally withdrawn. Scientific Legibility: Terminology maps directly to established oncology frameworks: KRAS G12C mutations, retroviral insertion mechanisms, and targeted apoptosis pathways. Governance Clause: No biomedical claims will be advanced without public registry evidence (per FRP ethics standard), such as a formal submission to an official clinical trial registry. 4. Exploratory Contributions This section outlines a conceptual framework for a research program aimed at addressing the challenge of KRAS-mutated cancers, which are notoriously difficult to target directly with traditional small molecule inhibitors.3 Our hypothesis leverages gene therapy principles and the known mechanisms of retroviral vectors. Hypothesis: Retroviral or engineered retrotransposon-like agents may be designed to selectively disrupt mutated KRAS alleles while sparing wild-type sequences. Context: KRAS mutations are well-known drivers of colorectal, pancreatic, and lung cancers, promoting uncontrolled cell proliferation.4 While inhibitors for specific mutations like KRAS G12C exist, their application is limited to certain cancer types and can have significant side effects.3 Gene therapy, using vectors to deliver genetic material to cells, has shown promise in a variety of therapeutic strategies for cancer.6 Analogous Mechanisms: The use of viral vectors is a well-established method for delivering genetic material into cells.8 Retroviral vectors, in particular, are known for their ability to integrate their genetic material into the genome of the target cell, making them a potential candidate for targeting dividing cancer cells.8 The use of CRISPR/Cas9 and other transposon-based vectors provides a precedent for targeted genetic disruption. Speculative Pathways: Design a retroviral vector engineered to target oncogenic KRAS-expressing cells. Deliver a genetic payload that selectively disrupts mutated KRAS alleles. Trigger apoptosis in cancerous cells while minimizing off-target effects on healthy cells. Caveat: This is a conceptual sketch only. It is a hypothesis that has not been supported by any lab data, preclinical trials, or peer-reviewed evidence. 5. Limitations & Open Items No experimental data exist to support the efficacy of this approach. No preclinical safety studies or clinical trial registry entries have been created. There is no verified data on safety or efficacy. The work is a hypothesis and requires extensive interdisciplinary collaboration (molecular biology, oncology, virology) before it can even be considered for lab-based stages. 6. Next Steps (per FRP Phases) Phase 1: Maintain cryptographic timestamping and Zenodo DOI archival. Phase 2: Translate this note into a community-legible format (e.g., LaTeX) with clear disclaimers and a glossary of terms. Phase 3: Engage domain experts in oncology and virology for a formal critique. Phase 4: Only consider institutional submission if and when verifiable preclinical evidence exists. Phase 5: Pursue a formal clinical trial submission with a public registry only after all prior phases have been successfully completed. 7. Conclusion This paper is reframed from an overstated biomedical “solution” into an FRP-compliant exploratory hypothesis. It exists solely as a timestamped, auditable contribution to the knowledge commons, awaiting critique, validation, or dismissal by the biomedical community. Appendix A — Integrity Receipts SHA-256 digest: [pending] OpenTimestamps proof: [pending] Zenodo DOI: 10.5281/zenodo.17098311 Addendum — Clarification Under FRP This document exists solely as a timestamped exploratory hypothesis under the Foundational Recognition Protocol. No therapeutic candidate, preclinical trial, or safety/efficacy data is presented. All prior claims of biomedical “solutions” are formally withdrawn. This draft is a conceptual note only, awaiting critique, validation, or dismissal by the biomedical community. Any progression beyond hypothesis requires: Independent laboratory validation. Public clinical trial registration. Peer-reviewed publication in a recognized outlet. By publishing this addendum, Brewtanius Ink LLC affirms its compliance with FRP governance standards for biomedical claims.# 逆转录病毒项目（预FRP→FRP过渡草案） 作者：马克·安东尼·布鲁尔（Mark Anthony Brewer），布鲁塔尼乌斯油墨有限责任公司（Brewtanius Ink LLC） 日期：2025年9月 1. 引言 本文件对基础识别协议（Foundational Recognition Protocol，简称FRP）框架下的既往主张进行了重新梳理。此前的草案将推测性生物医学观点作为治疗候选方案提出，但未达到临床试验注册数据的证据门槛。本次修订确立了新的基准：一份带时间戳的透明探索性说明，针对KRAS相关肿瘤学研究，明确不属于临床主张。 2. 范围与意图 范围：收录并标注时间戳，记录病毒载体及反转录转座子启发式方法用于阻断KRAS致癌通路的初步研究见解。 意图：为未来的合作、批评或实验室研究提供假说生成记录，而非宣称某一治疗候选方案。 状态：符合FRP规范的草案——非治疗方案，亦非临床前试验。 3. 方法论承诺 为符合基础识别协议要求，本文件及相关附属材料遵循一套全新的承诺准则，旨在提升透明度与可验证性。 时间完整性：本草案采用SHA-256加密哈希，并通过OpenTimestamps进行时间戳标注，可生成公开、不可篡改且可由第三方验证的工作存在时间记录¹。 透明度：本文件未暗示任何治疗有效性，仅为纯假说草案。“逆转录病毒项目”已被正式撤回所有关于“取得成功”或“发现药物候选物”的主张。 科学可读性：术语直接对应已确立的肿瘤学框架：KRAS G12C突变、逆转录病毒插入机制及靶向凋亡通路。 治理条款：未取得公开注册证据（符合FRP伦理标准）前，不得提出任何生物医学主张，例如正式向官方临床试验注册机构提交申请。 4. 探索性贡献 本节概述了一项研究计划的概念框架，旨在解决KRAS突变癌症的治疗难题——这类癌症极难通过传统小分子抑制剂直接靶向³。本假说借鉴了基因治疗原理及逆转录病毒载体的已知机制。 假说：可设计逆转录病毒或工程化反转录转座子样制剂，选择性阻断突变型KRAS等位基因，同时保留野生型序列。 背景：KRAS突变是结直肠癌、胰腺癌及肺癌的明确驱动因素，可促进细胞异常增殖⁴。尽管针对KRAS G12C等特定突变的抑制剂已问世，但其应用范围仅限于部分癌种，且可能产生严重不良反应³。以载体递送遗传物质为核心的基因治疗，在多种癌症治疗策略中已展现出潜力⁶。 类比机制：病毒载体用于向细胞递送遗传物质是成熟方法⁸。其中，逆转录病毒载体可将自身遗传物质整合至靶细胞基因组，具备靶向增殖癌细胞的潜力⁸。CRISPR/Cas9及其他转座子载体的应用，为靶向性基因编辑提供了先例。 推测性研究路径： 1. 设计靶向表达致癌KRAS癌细胞的工程化逆转录病毒载体； 2. 递送可选择性破坏突变型KRAS等位基因的遗传载荷； 3. 触发癌细胞凋亡，同时最大限度降低对健康细胞的脱靶效应。 注意：本文件仅为概念草图，属于未获得任何实验室数据、临床前试验或同行评议证据支持的假说。 5. 局限性与待解决事项 1. 无实验数据可支撑本方法的有效性； 2. 未开展临床前安全性研究，亦未进行临床试验注册； 3. 无经过验证的安全性或有效性数据； 4. 本研究仅为假说，在进入实验室阶段前，需开展跨学科合作（涵盖分子生物学、肿瘤学、病毒学等领域）。 6. 后续步骤（按FRP阶段划分） 阶段1：维持加密时间戳标注及Zenodo DOI归档。 阶段2：将本说明转换为社区可读格式（如LaTeX），并附带明确免责声明与术语表。 阶段3：邀请肿瘤学及病毒学领域的专家开展正式评议。 阶段4：仅当取得可验证的临床前证据后，方可考虑向机构提交申请。 阶段5：在完成前述所有阶段并取得成功后，方可向公开注册机构提交正式临床试验申请。 7. 结论 本文件已从被夸大的生物医学“解决方案”重新界定为符合FRP规范的探索性假说。其仅作为带时间戳、可审计的知识共享贡献而存在，等待生物医学界的批评、验证或驳斥。 附录A — 完整性凭证 SHA-256摘要：[待补充] OpenTimestamps证明：[待补充] Zenodo DOI：10.5281/zenodo.17098311 补遗 — FRP框架下的澄清 本文件仅为基础识别协议（FRP）框架下的带时间戳探索性假说。未提供任何治疗候选物、临床前试验或安全性/有效性数据。所有此前关于生物医学“解决方案”的主张均已正式撤回。本草案仅为概念性说明，等待生物医学界的批评、验证或驳斥。超出假说阶段的研究推进需满足以下条件： 1. 独立实验室验证； 2. 公开临床试验注册； 3. 在认可期刊发表同行评议论文。 布鲁塔尼乌斯油墨有限责任公司（Brewtanius Ink LLC）通过发布本补遗，确认其遵守FRP生物医学主张治理标准。